SEC Tracker
Get the app

Atossa Therapeutics ATOS

Atossa Therapeutics reports Q3 2026 financial results

Atossa Therapeutics (ATOS) filed an 8-K with the SEC on Nov 10, 2026, 8:15 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Operating expenses decreased to $5.9 million for Q3 2026
  2. Company anticipates FDA IND clearance for (Z)-endoxifen in 2027
  3. CVR agreement entitles holders to 25% of net proceeds from potential PRV sale up to $50 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Atossa Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.